Breaking News Instant updates and real-time market news.

ISRG

Intuitive Surgical

$415.05

2.93 (0.71%)

, MDT

Medtronic

$79.84

1.25 (1.59%)

07:20
04/13/18
04/13
07:20
04/13/18
07:20

Cantor sees 'several reasons' for Intuitive Surgical's momentum continuing

Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Intuitive Surgical with a $490 price target after attending the Society of American Gastrointestinal and Endoscopic Surgeons meeting. There were several scientific sessions highlighting Intuitive's robot for a broad range of procedures, Bijou tells investors in a research note. The analyst sees "several reasons" to believe that the company's momentum will continue. He notes that the uncertain timing for Medtronic's (MDT) robot remains positive for Intuitive Surgical.

ISRG

Intuitive Surgical

$415.05

2.93 (0.71%)

MDT

Medtronic

$79.84

1.25 (1.59%)

  • 18

    Apr

  • 19

    Apr

  • 27

    Apr

  • 28

    Apr

  • 18

    May

ISRG Intuitive Surgical
$415.05

2.93 (0.71%)

01/26/18
ADAM
01/26/18
NO CHANGE
Target $410
ADAM
Hold
Intuitive Surgical price target raised to $410 from $380 at Canaccord
Canaccord analyst Jason Mills raised his price target on Intuitive Surgical to $410 from $380 following strong Q4 results. The analyst noted management reiterated guidance, which he believes is conservative. He notes valuation has ascended to unprecedented levels throughout 2017 and significantly above its previous peak multiple. As a result, Mill maintains his Hold rating on Intuitive Surgical shares.
01/26/18
RBCM
01/26/18
NO CHANGE
Target $430
RBCM
Sector Perform
Intuitive Surgical price target raised to $430 from $350 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Intuitive Surgical to $430 and kept his Sector Perform rating after Q4 earnings. Henry says the company has continued to spend aggressively to accelerate development on several pipeline technologies that will expand its total addressable market and allow the company to remain a premium player in the surgical robotics market despite the increasing competition.
01/26/18
STFL
01/26/18
NO CHANGE
Target $480
STFL
Buy
Intuitive Surgical price target raised to $480 from $400 at Stifel
Stifel analyst Rick Wise noted that Intuitive Surgical management reiterated its previously provided 2018 procedure growth outlook for 11%-15% growth, but he points out that over the last several years initial procedure growth guidance has ultimately proved to be conservative. While he thinks the shares may experience some transient softness following the quarterly report and guidance, he would be a buyer on weakness. Wise raised his price target on Intuitive Surgical shares to $480 and keeps a Buy rating on the stock.
02/07/18
PIPR
02/07/18
NO CHANGE
Target $405
PIPR
Neutral
Piper sees limited competition for Intuitive Surgical over next two years
After digging into many of the companies developing a soft tissue surgical system that may be viewed as competitive to Intuitive Surgical's da Vinci family, Piper Jaffray analyst Matt O'Brien does not believe any of the new systems will meaningfully impact Intuitive Surgical's ability to place robots or perform cases in 2018 or 2019. The analyst says he would not be surprised to see a bit of pricing pressure materialize on Intuitive starting in 2019 and have more impact in 2020, which he believes "could impact results somewhat." O'Brien expects volatility around the stock as the approval/expanded indications occur, but he doubts the news will "severely derail the name in the near term." The analyst keeps a Neutral rating on Intuitive Surgical with a $405 price target.
MDT Medtronic
$79.84

1.25 (1.59%)

03/12/18
WBLR
03/12/18
NO CHANGE
WBLR
Outperform
Insulet announced coverage win with UnitedHealth, says William Blair
Insulet (PODD) on Friday announced it had established a new contract with UnitedHealthcare (UNH), which would provide its patients with in-network, durable medical equipment coverage for Omnipod beginning April 1, William Blair analyst Margaret Kaczor tells investors in a research note. This is another coverage win for Insulet as UnitedHealth represents almost 50M lives in the United States, the analyst adds. She notes Insulet has had limited access to historically a Medtronic (MDT) has been UnitedHealth's preferred, in-network DME insulin pump provider since mid-2016. Kaczor views the announcement as "another improvement in patient access to Omnipod." She thinks Insulet "continues to fire on all cylinders" and keeps an Outperform rating on the shares.
03/12/18
PIPR
03/12/18
NO CHANGE
PIPR
Overweight
Medtronic FDA news a 'nice win' for Dexcom in near-term, says Piper Jaffray
Piper Jaffray analyst JP McKim noted that Medtronic's (MDT) Guardian Connect system received FDA approval, but did not receive a non-adjunctive claim, which Dexcom (DXCM) and Abbott's (ABT) Libre have. The Guardian Connect system will not get Medicare coverage because of this, said McKim, who called the news a "nice win" for Dexcom in the near-term. While Kim does see Medtronic's system getting the claim eventually, he does not expect the Guardian Sensor to be a material threat to Dexcom in 2018 on a standalone basis, calling Medtronic a "pump first company." He keeps an Overweight rating on Dexcom shares.
03/16/18
NEED
03/16/18
DOWNGRADE
NEED
Underperform
Mazor Robotics downgraded to Underperform from Hold at Needham
Needham analyst Mike Matson downgraded Mazor Robotics (MZOR) to Underperform from Hold, forecasting a "significant" slowdown in the company's growth this year as well as more intense competition in the robotics space. Matson adds that Mazor's valuation is priced to a "best case scenario" that is unlikely to be achieved while an acquisition by Medtronic (MDT) is also "extremely unlikely".
04/11/18
RILY
04/11/18
INITIATION
Target $26.5
RILY
Buy
Intricon initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Intricon (IIN) with a Buy rating and $26.50 price target. The analyst says the company's partnership with Medtronic (MDT) offers steady growth while new legislation is favorable.

TODAY'S FREE FLY STORIES

07:20
07/23/18
07/23
07:20
07/23/18
07:20
General news
Treasury Market Outlook: Treasury yields have dipped lower »

Treasury Market Outlook:…

CNC

Centene

$135.45

0.175 (0.13%)

07:19
07/23/18
07/23
07:19
07/23/18
07:19
Initiation
Centene initiated  »

Centene initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 10

    Aug

  • 23

    Oct

  • 14

    Dec

OMER

Omeros

$19.63

-0.42 (-2.09%)

07:19
07/23/18
07/23
07:19
07/23/18
07:19
Hot Stocks
Omeros initiates sales of Omidria in Europe, satisfies 'sunset clause' »

Omeros announced initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$20.84

0.07 (0.34%)

07:19
07/23/18
07/23
07:19
07/23/18
07:19
Initiation
Lovesac initiated  »

Lovesac initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

07:17
07/23/18
07/23
07:17
07/23/18
07:17
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$45.69

-0.5 (-1.08%)

07:16
07/23/18
07/23
07:16
07/23/18
07:16
Conference/Events
21st Century Fox to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

SESN

Sesen Bio

$1.86

-0.05 (-2.62%)

07:16
07/23/18
07/23
07:16
07/23/18
07:16
Initiation
Sesen Bio initiated  »

Sesen Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$20.81

0.19 (0.92%)

07:14
07/23/18
07/23
07:14
07/23/18
07:14
Hot Stocks
Intra-Cellular announces publication highlighting ITI-214 »

Intra-Cellular Therapies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYB

RYB Education

$21.21

-0.33 (-1.53%)

07:14
07/23/18
07/23
07:14
07/23/18
07:14
Initiation
RYB Education initiated  »

RYB Education initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

-0.575 (-5.03%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Hot Stocks
Hi-Crush Partners raises quarterly distribution to 75c per unit »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

ACRE

Ares Commercial

$13.99

-0.05 (-0.36%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Initiation
Ares Commercial initiated  »

Ares Commercial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BPL

Buckeye Partners

$33.10

0.01 (0.03%)

07:13
07/23/18
07/23
07:13
07/23/18
07:13
Downgrade
Buckeye Partners rating change  »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

BV

BrightView

$21.95

0.14 (0.64%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

-0.575 (-5.03%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Hot Stocks
Hi-Crush Partners acquires FB Industries »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

ALNY

Alnylam

$105.86

-0.36 (-0.34%)

07:11
07/23/18
07/23
07:11
07/23/18
07:11
Hot Stocks
Alnylam announces presentations from APOLLO Phase 3 study of patisiran at PNS »

Alnylam announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Aug

MPWR

Monolithic Power

$140.71

-1.05 (-0.74%)

07:10
07/23/18
07/23
07:10
07/23/18
07:10
Conference/Events
Monolithic Power management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

HTHT

China Lodging

$41.02

0.76 (1.89%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
China Lodging management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 22

    Aug

IRWD

Ironwood

$20.03

-0.035 (-0.17%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Initiation
Ironwood initiated  »

Ironwood initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLIR

Flir Systems

$53.96

-0.55 (-1.01%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
Flir Systems management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

ARCT

Arcturus Therapeutics

$8.40

-0.09 (-1.06%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Hot Stocks
Arcturus achieves program milestones, refines agreement with CF Foundation »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$46.43

(0.00%)

07:08
07/23/18
07/23
07:08
07/23/18
07:08
Conference/Events
Reata Pharmaceuticals to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LAD

Lithia Motors

$95.34

-0.85 (-0.88%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Hot Stocks
Lithia Motors announces Erik Lewis as CHRO »

Lithia Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

KALA

Kala Pharmaceuticals

$12.28

-0.19 (-1.52%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Initiation
Kala Pharmaceuticals initiated  »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Aug

JMEI

Jumei

$2.07

-0.05 (-2.36%)

07:06
07/23/18
07/23
07:06
07/23/18
07:06
Hot Stocks
Jumei announces $27.6M in share repurchase since April »

Jumei announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$46.57

0.47 (1.02%)

07:05
07/23/18
07/23
07:05
07/23/18
07:05
Hot Stocks
Acceleron reports preliminary results from Part 1 of ACE-083 Phase 2 trial »

Acceleron Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.